Tonix Pharmaceuticals (TNXP) announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute, KEMRI, to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 as a vaccine to prevent mpox and smallpox. Tonix will be the sponsor and KEMRI will lead the execution of the proposed clinical trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNXP:
- Tonix Pharmaceuticals (TNXP) Q3 Earnings Cheat Sheet
- Tonix Pharma Showcases Promising TNX-801 Vaccine Results
- Tonix Pharmaceuticals presents data on TNX-801 at World Vaccine Congress
- Tonix Pharma Secures Defense Contract for Antiviral Development
- Tonix Pharmaceuticals receives first contract payment from U.S. DoD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
